Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $36,000 | reported | |
| FY 2024 | 2024-12-31 | $61,000 | reported | |
| FY 2023 | 2023-12-31 | $130,000 | reported | |
| FY 2022 | 2022-12-31 | $84,683,000 | reported | |
| FY 2021 | 2021-12-31 | $10,650,000 | reported | |
| FY 2020 | 2020-12-31 | $7,756,000 | reported | |
| FY 2019 | 2019-12-31 | $657,000 | reported |
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
Twelve months to Sep 30, 2026 · derived
Lyell Immunopharma, Inc. is the 251st largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
Latest filing Nov 13, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2022 | — | $0.00 | $0.00 | — | 249.61M sh | +1.7% | — |
| FY2021 | — | $0.00 | $0.00 | — | 245.39M sh | +1,476.1% | — |
| FY2020 | — | $11.81M | $11.81M | — | 15.57M sh | — | — |
| FY2019 | — | $185.00K | $185.00K | — | — | — | 0.8% |
103 managers · Quarter ended Sep 30, 2026All holders ›
28